Number needed to screen for acute revascularization trials in stroke: Prognostic and predictive imaging biomarkers

Abstract

Objective

To systematically assess imaging biomarkers on CT-based multimodal imaging for their being predictive versus prognostic biomarkers for intravenous and endovascular (IA) revascularization therapy, and for their prevalence.

Methods

Our retrospective study included patients suspected of acute ischemic stroke with admission work-up including a non-contrast head CT, perfusion CT, and CT angiography. Modified Rankin scores at 90 days were used as outcomes. For each imaging biomarker, the effect size of the test of interaction between the presence of the biomarker and the treatment effect was calculated, allowing the inference of a total sample size. The total sample size required was combined with the prevalence of the biomarker to determine the number needed to screen.

Results

In the 0–4.5-h time window, the two predictive biomarkers associated with the smallest number needed to screen were perfusion CT penumbra ≥ 20% (404 NNS) and CT angiography collateral score ≥ 2 (581 NNS). In the 3–9-h time window, the four predictive biomarkers associated with the smallest number needed to screen were clot burden score (CBS) on CT angiography (1181 NNS), clot length ≥ 10 mm (1924 NNS), CBS and clot length ≥ 10 mm (1132 NNS), and CBS and perfusion CT penumbra ≥ 100% (1374 NNS). Perfusion CT ischemic core was a prognostic biomarker in both time windows.

Interpretation

Predictive biomarkers need to be differentiated from prognostic biomarkers when being considered to select patients for a trial, and their prevalence should be assessed to determine the number needed to screen and overall feasibility of the trials.

Keywords

Stroke imaging tissue-type plasminogen activator endovascular treatment biomarker revascularization

Get full access to this article

View all access options for this article.

References

Atkinson

Colburn

DeGruttola

. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.

Parsons

Albers

. MR rescue is the glass half-full or half-empty? Stroke 2013; 44: 2055–2057.

Pexman

Barber

Hill

. Use of the Alberta stroke program early CT score (aspects) for assessing CT scans in patients with acute stroke. Am J Neuroradiol 2001; 22: 1534–1542.

Launes

Ketonen

. Dense middle cerebral artery sign: An indicator of poor outcome in middle cerebral artery area infarction. J Neurol Neurosurg Psychiatr 1987; 50: 1550–1552.

Shobha

Bal

Boyko

. Measurement of length of hyperdense MCA sign in acute ischemic stroke predicts disappearance after IV TPA. J Neuroimaging 2014; 24: 7–10.

Puig

Pedraza

Demchuk

. Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator. Am J Neuroradiol 2012; 33: 90–96.

Tan

Demchuk

Hopyan

. Ct angiography clot burden score and collateral score: Correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. Am J Neuroradiol 2009; 30: 525–531.

Torres-Mozqueda

Yeh

. An acute ischemic stroke classification instrument that includes CT or MR angiography: the Boston acute stroke imaging scale. Am J Neuroradiol 2008; 29: 1111–1117.

Tan

Demchuk

Hopyan

. Ct angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. Am J Neuroradiol 2009; 30: 525–531.

10.

Wintermark

Flanders

Velthuis

. Perfusion-CT assessment of infarct core and penumbra receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37: 979–985.

11.

van der Zwan

Hillen

Tulleken

Dujovny

. A quantitative investigation of the variability of the major cerebral arterial territories. Stroke 1993; 24: 1951–1959.

12.

Zhu

Michel

Aghaebrahim

. Prediction of recanalization trumps prediction of tissue fate the penumbra: a dual-edged sword. Stroke 2013; 44: 1014–1019.

13.

Kidwell

Jahan

Gornbein

. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013; 368: 914–923.

14.

Friedman

Koroshetz

Qureshi

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1996; 334: 1405.

15.

Hacke

Kaste

Bluhmki

. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–1329.

16.

del Zoppo

Higashida

Furlan

Pessin

Rowley

Gent

. Proact: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4–11.

17.

Berkhemer

Fransen

Beumer

. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11–20.

18.

Goyal

Demchuk

Menon

. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372: 1019–1030.

19.

Saver

Goyal

Bonafe

. Stent-retriever thrombectomy after intravenous t-pa vs. T-pa alone in stroke. N Engl J Med 2015; 372: 2285–2295.

20.

Parsons

Spratt

Bivard

. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099–1107.

21.

Campbell

Mitchell

Kleinig

. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372: 1009–1018.